

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
November 07, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): November 7, 2013

LA JOLLA PHARMACEUTICAL COMPANY  
(Exact name of registrant as specified in its charter)

California (State or other jurisdiction of incorporation or organization)	0-24274 (Commission File Number)	33-0361285 (I.R.S. Employer Identification No.)
---------------------------------------------------------------------------------	----------------------------------------	-------------------------------------------------------

4660 La Jolla Village Drive, Suite 1070, San Diego, California (Address of Principal Executive Offices)	92122 (Zip Code)
---------------------------------------------------------------------------------------------------------------	---------------------

Registrant's telephone number, including area code: (858) 207-4264

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 7.01 REGULATION FD DISCLOSURE.

On November 7, 2013, La Jolla Pharmaceutical Company (the “Company”) hosted a poster at Kidney Week 2013 the annual meeting of the American Society of Nephrology. A copy of the poster from the event is attached hereto as Exhibit 99.2 and is also posted on the Company’s website at <http://www.ljpc.com>. In connection with the poster and data presented, the Company issued a press release on November 7, 2013, a copy of the press release is attached hereto as Exhibit 99.1.

The information set forth under Item 7.01 and in Exhibit 99.1 and 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits. The following exhibit is filed with this report on Form 8-K:

Exhibit No.	Description
99.1	Press release dated November 7, 2013.
99.2	Poster used in connection with data presented at ASN November 7, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: November 7, 2013

By: /s/ George F. Tidmarsh

Name: George F. Tidmarsh, M.D., Ph.D.

Title: President and Chief Executive Officer